U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

 Complete if Known

 Application Number
 09/581,511

 Fling Date
 October 6, 2000

 First Named Inventor
 Raymond ANDERSEN

 Art Unit
 1654

 Examiner Name
 Lukton, David

 Attoney Docket Number
 108281-00000

(Use as many sheets as necessary)
Sheet 1 of 2

Substitute for form 1449A/PTO

U. S. PATENT DOCUMENTS Examiner Document Number Publication Date Name of Patentee or Pages, Columns, Lines, Where Initials* MM-DD-YYYY Applicant of Cited Document Relevant Passages or Relevant Number-Kind Code^{2 (Fknown)} Figures Appear 7D.L. us-6.194.578 Pfizer, Inc. 02-27-2001 US-US-HC. us-IIS. US-110 HS. 115 US-119. US-IIS. us. US-115. US-

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁰
/D.L./		EP 1 002 802	12-08-2004	Pfizer Products, Inc.		
						-
	_					-

(Examiner Signature	/David Lukton/	Date Considered	10/09/2008

"EXAMINER: hittal if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through datalor if not in conformance and not considered include copy of this form with next communication to applicant. Applicants unique classified segaration number (optional). "See Kinds Codes of USPTO Patent Documents at www.usglo.gov or MPEP 901.04. "Enter Office that issued the document, by the two-letter code (WIPO) Standard ST 31, "For Japanese patent documents, the indication of the year of the reging of the Emperor must procede the serial number of the patent document with documents that the patent document with of coursent by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. "Applicant is to place a check mark here if English language Translation is attacked."

This collection of information is required by 37 CFR 197 and 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 38 U.S.C. 122 and 37 CFR 1.1. This collection is estimated to false 2 hours to compete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comment on the amount of time you require to complete this form and/or supgestions for eviduring this burder, ahould be sent to the Chief Information CV. Shart and Trademark Office, P.O. Box 1459, Alexandria, VA. 22315-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patters, P.O. Box 1450, Alexandria, VA. 22315-1430, DO NOT SEND THIS ADDRESS.

Approved for use through 07/31/2008, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

108281-00000

Under the Paperwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number Substitute for form 1449B/PTO Complete if Known Application Number 09/581.511 INFORMATION DISCLOSURE Filing Date October 6, 2000 STATEMENT BY APPLICANT First Named Inventor Raymond ANDERSEN Art Unit 1654 (Use as many sheets as necessary) Examiner Name Lukton, David

Attorney Docket Number

Sheet

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
/D.L./					
		L-Valylglycine (CAS number 686-43-1)	.1		
/D.L./		SKEHAN, P. et al. "New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening, Journal of National Cancer Institute vol. 82, no. 13, pp. 1107-1112, 1990			
	1				
	-		-		
	ļ		\perp		

Examiner Signature	/David Lukton/	Date Considered	10/09/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFT 14 May.

188. The information is required by 37 CFT 14 May.

189. The information is required by 32 CFT 14 May.

189. The information is required by 34 CFT 14 May.

189. The information is required by 34 CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The information is required by 34 US CFT 14 May.

189. The informat